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The details of intracellular transport pathways for glycosylated proteins remain incompletely described. We previously 
described a mutant Rous sarcoma virus envelope glycoprotein (gp),/~26, with an altered membrane-spanning domain that 
was targeted to lysosomes after traversing the trans-Golgi. This mutant protein was not detectable on the cell surface by 
immunofluorescence, but its pathway for degradation remained unclear. To investigate this we have employed a second 
env  mutation, S19, that results in a protein which is defective for normal cleavage/activation by intracel.lular enzymes, but 
remains susceptible to cleavage by extracellutar proteases. Cleavage/activation of the double mutant by trypsin, which 
could only occur if it was exposed on the cell surface, was observed, indicating that the plasma membrane is an intermediate 
destination in the transport of this mutant protein. To substantiate these results, cells expressing the /~26 glycoprotein 
were incubated with an antibody specific for the native protein in the presence of chloroquine. The specific accumulation 
of this antibody/gp complex in vesicles, as detected by internal immunofiuorescence, onfirmed the trypsin cleavage results. 
We conclude that this rapidly degraded mutant protein is transported from the trans-Golgi to the cell surface, where it is 
only transiently exposed, and then rapidly endocytosed and lysosomaily degraded. The relevance of these results to the 
targeting of lysosomal proteins is discussed. © 1995 Academic Press, Inc. 
INTRODUCTION 
The synthesis, transport, and processing of retroviral 
glycoproteins mimic that of host cell glycoproteins. These 
proteins utilize the host cell machinery for synthesis, 
cleavage, and even sugar modification of their glycopro- 
teins, thus it may be possible to discern generalized 
patterns of cellular protein targeting by observing trans- 
port of these viral proteins. In this study we examine 
the transport of a mutant viral glycoprotein, #26, which 
contains a charged amino acid in its membrane anchor. 
The glycoproteins of retroviruses typically contain two 
subunits, a surface component, SU, and a transmem- 
brane component, TM. The SU proteins are involved in 
receptor binding on susceptible cells. The TM protein 
anchors the glycoprotein complex in the viral membrane 
and appears to play a role in virus/cell membrane fusion. 
The Rous sarcoma virus (RSV) glycoprotein is synthe- 
sized as a 95-kDa high-mannose precursor, Pr95 enV 
(Bosch and Schwarz, 1984; Hunter eta/ . ,  1983) in the 
rough ER and is cleaved by cellular proteases in the 
Golgi complex to yield gp85(SU) and gp37(TM), which 
are terminally glycosylated and covalently linked through 
disulfide bonds (England eta/.,  1977; Hayman, 1978; Pa- 
lade, 1975; Perez and Hunter, 1987). 
The TM glycoprotein of RSV has been described as 
having a 149-amino acid external domain, a 27-amino 
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acid membrane-spanning anchor domain, and a 22- 
amino acid cytoplasmic domain (Hunter et al., 1983). 
More recent studies, however, have shown that two cys- 
teine residues in the membrane-spanning domain are 
sites of palmitylation, raising the possibility that the cyto- 
plasmic domain may be as long as 29 amino acids (Miller 
et al., submitted for publication). The function of the cyto- 
plasmic domain remains unclear, it has been proposed 
from chemical cross-linking studies that the cytoplasmic 
domain has a specific interaction with the protein core 
of the virus particle (Gebhardt et al., 1984) and may be 
involved in virus formation. Env proteins which have a 
cytoplasmic domain truncated by 22 amino acids, how- 
ever, are still assembled into infectious virions (Perez et 
a/., 1987). 
We previously described a mutant glycoprotein, #26, 
which contains a charged residue within the membrane- 
spanning domain (Davis and Hunter, 1987). This mutant 
env gene was shown to program the synthesis of normal 
levels of Env precursor, which was transported with nor- 
mal kinetics to the trans-Golgi. However, no cell-surface 
accumulation of glycoprotein could be detected and the 
terminally glycosylated, mature cleavage products were 
rapidly degraded. In the presence of lysosomal inhibitors 
these products accumulated, indicating that the protein 
was being targeted to lysosomes where it was being 
degraded. In the current study, we have introduced a 
cleavage-site mutation to show that the lysosomally tar- 
geted protein is exposed on the cell surface. Moreover, 
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expression of the #26 mutant protein in CV-1 cells 
causes the specific endocytosis and accumulation of re- 
active antibody. These results confirm that the #26 mu- 
tant glycoprotein is transiently expressed on the cell sur- 
face prior to endocytosis and lysosomal degradation. The 
fate of the #26 protein may indicate a more generalized 
pathway for lysosomally targeted glycoproteins. 
MATERIALS AND METHODS 
Cell culture 
African green monkey kidney cells (CV-1 cells) were 
obtained from the American Type Culture Collection 
(Rockville, MD). CV-1 cells were maintained in Dulbec- 
co's modified Eagle's medium (DMEM) containing 10% 
fetal bovine serum. 
DNAs and plasmids 
pSVenvKX, an env-SV40 expression vector containing 
a wild-type RSV glycoprotein gene and the ff26 
(pSVenvKX-#26) and S19 (pSVenvKX-S19) mutant genes, 
has been previously described (Davis and Hunter, 1987; 
Dong et al., 1992). The doubly mutant glycoprotein gene 
containing the #26 and $19 mutations was constructed 
by replacing a 507-bp Smal/Xbal fragment of the 
pSVenvKX-S19 plasmid with the Smal/Xbal fragment de- 
rived from pSVenvKX-#26. The presence of both muta- 
tions within the pSVenvKX-#26/S19 plasmid was con- 
firmed by dideoxy-sequencing utilizing the Sequenase 
system (United States Biochemical Corp., Cleveland, 
OH). All plasmids were propagated in Escherichia coil 
DH-1 cells and purified using cesium chloride gradients 
(Maniatis et aL, 1982). 
Recombinant SV40 virus production and use 
Recombinant SV40 virus stocks were prepared as pre- 
viously described (Davis and Hunter, 1987). Briefly, 
pSVenvKX plasmids containing wild-type, #26, $19, or 
#26/$19 RSV env genes were digested with Kpnl (to re- 
move the plasmid sequences) and self-ligated, in order 
to juxtapose the SV40 late promoter to the 5' end of the 
envgenes. These DNAs were cotransfected with comple- 
menting d11055 helper virus DNA (Gething and Sam- 
brook, 1981; Wills eta/., 1983) into CV-1 cells to produce 
recombinant SV40 virions. At 5 days post-transfection, 
the cells were repeatedly frozen and thawed and then 
sonicated to release virions. Undiluted viral stocks were 
used to infect CV-1 cells to generate high-titer working 
stocks. Working stocks were generally diluted 1=25 to 
1,50 prior to infection of CV-1 cells in experiments exam- 
ining envelope gene expression. Viral protein synthesis 
was assayed in infected cells at 48-72 hr postinfection. 
Metabolic labeling 
At 48-72 hr postinfection with recombinant SV40 virus 
stocks, CV-1 cells were labeled for 30 min with 375 #Ci/ 
ml [3H]leucine (145 Ci/mM, Dupont NEN, Wilmington, DE) 
in leucine-deficient MEM (Gibco/BRL). After the 30-min 
pulse at 37 °, cells were either lysed or complete medium 
(plus or minus chloroquine and trypsin) was added for an 
additional 4 hr prior to lysis. Lysis, immunoprecipitation, 
SDS-PAGE analysis, and fluorography were performed 
as previously described (Davis and Hunter, 1987; Wills 
et aL, 1983, 1984). 
Chloroquine and trypsin treatment 
To prevent lysosome-mediated egradation of the #26 
and ff26/S19 mutant proteins, chloroquine was added to 
the culture media to a final concentration of 100 #M in 
the indicated plates during the 4-hr chase period of the 
metabolic labeling experiment. To determine whether the 
#26/S19 mutant glycoprotein was being exposed on the 
cell membrane prior to internalization, trypsin was also 
added to the culture medium to a final concentration of 
5 #g/ml during the 4-hr chase period. This concentration 
of trypsin was established experimentally as the optimal 
amount to cleave the surface-expressed $19 protein effi- 
ciently to its mature products (gp85 and gp37) without 
inducing aberrant cleavage of the products. 
Surface immunofluorescence 
Steady-state levels of cell surface-expressed glycopro- 
teins were assayed by immunofluorescence. Glycopro- 
tein-expressing CV-1 cells on glass coverslips were 
washed three times with ice cold serum-free DMEM. 
Chicken anti-PrO serum was diluted 1=25 in serum-free 
DMEM, and 25 #1 of this was added to each coverslip. 
After incubation on ice for 30 min, the coverslips were 
washed three times in serum-free DMEM, and 25 #1 of 
a 1=25 dilution of FITC-labeled rabbit anti-chicken IgG 
(Southern Biotechnology Associates, Inc., Birmingham, 
AL) was then added to each coverslip. This was incu- 
bated for 30 min on ice. After washing the coverslips 
three times in serum-free DMEM, the cells were fixed in 
3.7% formalin in PBS for 30 min on ice. The fixed cells 
were washed twice with PBS and once with distilled 
water and visualized by fluorescent microscopy. 
Internal immunofluorescence 
Internalization of specific and nonspecific antibodies 
by the lysosomally targeted #26 glycoprotein was as- 
sayed by immunofluorescence. Glycoprotein-expressing 
CV-1 cells on glass coverslips were incubated for 4 hr 
at 37 ° with a 1,25 dilution of chicken anti-PrO, chicken 
anti-PrA, or rabbit anti-M-PMV antibodies in the presence 
of 100 #M chloroquine. Cells expressing the M-PMV gly- 
coprotein complex, expressed from similar recombinant 
SV40 stocks (Brody et al., 1992), were processed in an 
identical manner to the RSV glycoprotein-expressing 
cells to verify that SV40 infection did not induce nonspe- 
cific accumulation of the antibodies. 
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Precursor 
Cleavage ~ Transmembrane Anchor 
gp85 ~ gp~/ 
Wt Arg'Arg'Lys'Arg'¥'Ser . . . . . . . . . . . . . . . .  I L , , ,  Cys-Leu-Pro-Cys,-'~ ,, 
~26 Arg-Arg-Lys-Arg- -Ser . . . . .  . . . . . . . . . . .  f : - ' "  Cys-Arg-Pro-'Oys,-'~,--. 
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p26/$19 " Ser-Arg-Glu-Arg-X-Ser . . . . . . . . . . . . . . . .  I ' ' "  Cys-Arg-Pro-Cys--~---,- 
FIG. 1. Amino acid changes within the Rous sarcoma virus envelope glycoprotein. Listed are the partial amino acid sequences from the envelope 
glycoprotein of the wild-type virus (Wt). the #26 mutant, the $19 mutant (defective for intracellular cleavage of the precursor), and the #26/S19 
mutant (lysosomally targeted mutant defective for intracellular cleavage). 
Following incubation with the antibody-containing me- 
dium, the cells were washed twice with PBS and fixed 
for 1 hr on ice in 95% ethanol/5% acetic acid. Cells were 
washed three times with PBS with 3% BSA and then 
reacted with 25 #1 of a 1=25 dilution of FITC-labeled rabbit 
anti-chicken IgG or goat anti-rabbit IgG (Southern Bio- 
technology Associates, Inc.). After incubation at room 
temperature for 30 min, the fixed cells were washed 
twice with PBS containing 3% BSA. 
In some experiments, the cells were doubly stained 
for lysosomal vesicles using a 1,25 dilution of either 
monoclonal antibody 1 B5 (which reacts with a lysosomal 
marker, kindly provided by Mark Marsh) or monoclonal 
antibody H4B4 (reactive with human LAMP-2 glycopro- 
tein), in this case, the cells were washed an additional 
three times with PBS containing 3% BSA and incubated 
with 25 #1 of a 1,25 dilution of Texas red-labeled goat 
anti-mouse antisera (Southern Biotechnology Associ- 
ates, inc.). After a further incubation for 30 min at room 
temperature, the cells were washed and mounted as 
described above for fluorescence microscopy. 
RESULTS 
Construction of a mutant env  gene which encodes a 
conditionally cleaved, lysosomally targeted 
glycoprotein 
As described under Materials and Methods and de- 
picted schematically in Fig. 1, the #26 mutation (substitu- 
tion of arginine for leucine at residue 165 of gp37(TM)) 
which results in rapid lysosomal degradation of the ma- 
ture env gene products was engineered into a mutant 
envgene (mutant S19)that encodes a glycoprotein which 
cannot be cleaved by proteolytic enzymes present within 
the secretory pathway. The double mutant, #26/Sl 9, thus 
has a total of three amino acid substitutions, two in gp85 
and one in gp37. 
Steady-state levels of mutant RSV glycoproteins on 
the cell surface 
We demonstrated previously that the #26 protein was 
undetectable on the cell surface and was rapidly de- 
graded (Davis and Hunter, 1987). To confirm this previous 
observation and to show that the double mutant had a 
similar phenotype, we examined the surface expression 
of the wild-type and mutant proteins using surface immu- 
nofluorescence. The cleavage-defective $19 mutant ac- 
cumulated on the cell surface at a level similar to that 
of the wild-type glycoprotein (Figs. 2A and 2B). in con- 
trast, the ff26 and #26/$19 mutant glycoproteins were 
undetectable above background (Figs. 20 and 2D). The 
absence of surface expression was not due to the lack 
of expression, since these proteins could be immunopre- 
cipitated from duplicate monolayers (data not shown). 
Thus, despite the normal synthesis of glycoprotein, it was 
not possible to detect any accumulation of either the #26 
or #26/$19 mutant proteins on infected cell surfaces. 
Cleavage and accumulation of lysosomally targeted/ 
cleavage defective glycoproteins 
To determine whether the lysosomally targeted glyco- 
proteins were being transported first to the cell surface, 
we examined proteins expressed when trypsin and chlo- 
roquine were added to the culture medium, it has been 
demonstrated that the cleavage-defective $19 protein is 
not cleaved by intracellular proteases, but is susceptible 
to exogenously added trypsin (Dong et aL, 1992). Since 
chloroquine inhibits lysosomal degradation of the #26 
proteins, mature cleavage products of the ff26/$19 pre- 
cursor should accumulate in the presence of both re- 
agents if the doubly mutant glycoproteins are being ex- 
pressed on the plasma membrane. Figure 3 summarizes 
the results of a typical experiment. In cells infected with 
the #26 env-expressing recombinant SV40, a single pre- 
cursor protein, Pr95 e°v, was immunoprecipitated from 
pulse-labeled cells (Fig. 3, #26, lane P). During the chase 
period, the intensity of this band decreased, but no new 
bands corresponding to the terminally glycosylated 
cleavage products, gp85 and gp37, could be seen (Fig. 
3, #26, lane PC). In contrast, when the cells were chased 
in the presence of 100 #M chloroquine, significant levels 
of both gp85 and gp37 accumulated (Fig, 3, #26, lane 
PCC), and addition of 5 #g/ml of trypsin to the medium 
had no effect on these.proteins (Fig. 3, #26, lane PCCT). 
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FIG. 2. Surface expression of the RSV glycoproteins on CV-1 cells. The steady-state level of the wild-type and mutant glycoproteins was determined 
using indirect immunofluorescence. A chicken antiserum reactive with the RSV glycoproteins was used as a probe on intact, infected CV-1 cells. 
An intense fluorescence pattern was detectable on the surface of cells expressing the wild-type (A) or $19 (B) glycoproteins. The #26 (C) and/~26/ 
$19 (D) glycoprotein-expressing cells showed no surface fluorescence above background levels. 
Immunoprec ip i ta t ion  of pu lse - labe led  ce l ls  express ing  
the $19 mutant  y ie lded  s imi la r  leve ls  of the Pr95 precur -  
sor  (Fig. 3, $19, lane P). However ,  dur ing  the chase  no 
s ign i f i cant  decrease  in the in tens i ty  of the band was  
observed ,  and the presence  of te rmina l ly  g lycosy la ted  
precursor  was  apparent  f rom the broaden ing  and de-  
0. 
~26 ~26/$19 $19 
I -  I -  i -  
O O rO O O O 
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FIG. 3. Cleavage and accumulation of the doubly mutant RSV glycoproteins in infected cells, CV-1 cells expressing the mutant glycoproteins were 
pulse-labeled (P), pulse-labeled then chased for 4 hr (PC), or pulse-labeled then chased for 4 hr in the presence of chloroquine (PCC) or in the 
presence of chloroquine and trypsin (PCCT). Cells were lysed and Env proteins collected by immunoprecipitation, separated by electrophoresis, 
and visualized by autoradiography. The autoradiogram of the immunoprecipitated proteins demonstrates the accumulation of the mature, cleaved 
proteins containing the ff26 mutation in the presence of chloroquine. Only in the presence of added trypsin are proteins containing the $19 mutation 
cleaved. The doubly mutant glycoproteins, #26/S19, are accumulated in the presence of chloroquine, but are only cleaved to mature products in 
the presence of added trypsin in the culture medium. Both the lysosomally targeted /~26/$19 and surface-expressed $19 are shown to accumulate 
approximately equivalent amounts of cleaved protein in the presence of chloroquine and trypsin. 
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creased mobility of the band (Fig. 3, $19, lane PC). In 
the presence of chloroquine, slightly elevated levels of 
precursor were found, consistent with an inhibition of 
protein turnover (Fig. 3, S19, lane PC). In the presence 
of both chloroquine and trypsin, similar levels of gp85 
and gp37 were present in the S19 protein-expressing 
cells, analogous to that seen with #26 and wild type (not 
shown). Thus chloroquine has no effect on the exoge- 
nous cleavage of surface expressed $19 mutant protein. 
The double mutant, #26/S19, glycoprotein precursor 
was synthesized normally, and during the chase a signifi- 
cant proportion of the protein was turned over (Fig. 3, 
#26/$19, lanes P and PC). As with the #26 mutant, accu- 
mulation of the #26/$19 glycoprotein was observed in 
the presence of chloroquine. Of most interest, however, 
was the demonstration that addition of trypsin and chlo- 
roquine to the culture supernatant resulted in the efficient 
processing of the #26/$19 protein and the accumulation 
of similar levels of gp85 and gp37 to those seen with 
either single mutant. Thus, the lysosomally targeted, 
cleavage-defective proteins must be exposed in a quanti- 
tative fashion to the trypsin present in the culture super- 
natant and argues for transient expression on the cell 
surface. 
Expression of the p26 glycoprotein induces 
endocytosis and intracellular accumulation of type- 
specific neutralizing antibodies 
It was possible that trypsin might be endocytosed and 
introduced into a common vesicle with the #26/$19 pre- 
cursor where cleavage could occur (although this was 
unlikely, given the efficiency of precursor cleavage of the 
doubly mutant proteins). In order to obtain independent 
evidence of surface expression, cells expressing the #26 
glycoproteins were incubated at 37 ° in the presence of 
chloroquine and neutralizing antibodies specific for the 
Prague C strain of Rous sarcoma virus (chicken anti- 
PrC). Cells were then fixed and permeabilized, and cell- 
associated antibodies were detected by indirect immu- 
nofluorescence with an FITO-labeled rabbit anti-chicken 
IgG. The results of such an experiment are shown in 
Figs. 4A and 4B and demonstrate that large amounts of 
antibody accumulated within cytoplasmic vesicles in the 
#26-expressing cells. It is important o note that the anti- 
bodies appear to line the inner surface of structures that 
resemble empty vesicles rather than accumulating as a 
soluble molecule. Moreover, in experiments where these 
cells were counterstained with a rabbit anti-Env antibody, 
the chick-lgG vesicles were found to colocalize with 
those containing Env protein (data not shown) with no 
vesicle population staining only with the rabbit anti-Env 
antibodies. 
The uptake of the antibodies appeared to be highly 
specific since antibodies with an equal neutralizing titer 
against another strain of RSV (chicken anti-PrA) did not 
accumulate in cells expressing the #26 protein (Fig. 4C), 
even though these cells contained similar levels of Env- 
containing vesicles (data not shown). In addition, it does 
not appear that the specific accumulation of chicken anti- 
PrO antibody is an epiphenomenon associated with this 
specific antibody, because cells expressing the M-PMV 
glycoprotein, in place of the RSV glycoprotein, from the 
same SV40 vector did not accumulate antibody (Fig. 4D). 
Accumulation of mutant glycoproteins in the presence 
of chloroquine is in prelysosomal vesicles 
In order to determine approximately where in the endo- 
cytic pathway the #26 protein was accumulating in the 
presence of chloroquine, cells expressing the mutant gly- 
coproteins were fixed, permeabilized, and costained with 
an anti-Env antibody and a monoclonal antibody against 
a lysosc~mal protein. As can be seen in Fig. 5, the large 
vesicles that stain with the anti-Env antibody (Fig. 5A) do 
not colocalize with the predominantly small, perinuclear 
vesicles that stain with the anti-lysosomal protein anti- 
body, 1 B5 (Fig. 5B). In uninfected cells, no anti-Env stain- 
ing was observed (Fig. 5C), and a more extensive anti- 
lysosomal staining could be seen (Fig. 5D). Similar pat- 
terns of staining were seen when glycoprotein-express- 
ing ceils were treated similarly, with lysosomal staining 
utilizing monoclonal antibody H4B4, which is reactive 
with the human LAMP-2 glycoprotein (data not shown). 
Thus, as has been reported for other systems, chlo- 
roquine treatment appears to inhibit fusion of the endoso- 
mal vesicles with the lysosomes, resulting in accumula- 
tion of the/~26 protein in a prelysosomal vesicle. 
DISCUSSION 
The transport pathway of lysosomally targeted glyco- 
proteins from the Golgi apparatus to lysosomes remains 
unclear. Transport from the trans-Golgi network to the 
lysosomes might involve expression on the plasma mem- 
brane followed by endocytosis; alternatively, intracellular 
sorting in the Golgi could direct the proteins directly to 
endosomes/lysosomes without a cell-surface intermedi- 
ate. In this study we have demonstrated the appearance 
on the cell surface of a lysosomally targeted viral glyco- 
protein which is undetectable on the plasma membrane 
by conventional techniques. 
Previous studies on the transport of several lysosomal 
proteins suggest that both pathways are utilized. Several 
lysosomal glycoproteins have been reported to have a 
cell-surface intermediate prior to endocytosis. LEP100, a 
chicken lysosomal glycoprotein, has been shown to 
have a plasma membrane intermediate, as demonstrated 
by specific antibody uptake experiments (Lippincott- 
Schwartz and Fambrough, 1987). Surface expression of 
various other lysosomal proteins, the mouse LAMP-1 
(Chen et al., 1985) and human LAMP-1 and LAMP-2 
(Mane eta/., 1989) proteins, has been demonstrated with 
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FiG. 4. Specific antibody uptake and accumulation in cytoplasmic vesicles in #26 glycoprotein-expressing cells. CV-1 cells expressing the 
lysosomally targeted #26 proteins were incubated for 4 hr with either type-specific neutralizing anti-RSV antibodies (A and B) or antibodies directed 
to another RSV strain (C) in the presence of chloroquine. Secondary staining of the fixed, permeabilized cells demonstrated the specific accumulation 
of only the type-specific antibody in #26-expressing cells. Incubation of cells expressing the Mason-Pfizer monkey virus glycoprotein (D) with the 
type-specific anti-RSV antibody for 4 hr in the presence of chloroquine did not result in the specific accumulation of that antibody in those fixed 
cells. 
antibody binding studies. Lysosomal acid phosphatase 
(LAP) also undergoes a cell-surface intermediate prior 
to its transport to lysosomes as detected by cell-surface 
iodination experiments (Braun et al., 1989). The surface- 
expressed LAP molecules were eventually transported 
to lysosomes. In contrast, Tanaka et al. (1990) demon- 
strated that the majority of LAP did not undergo cell- 
surface expression. 
The alternative pathway, direct transport of lysosomal 
proteins from the trans-Golgi network to endosomal/lyso- 
somal vesicles without a cell-surface intermediate, has 
also been reported. The transport of Igp120 and Igp110, 
lysosomal glycoproteins 120 and 110, from the Golgi to 
lysosomes was demonstrated to have approximately 
equal transport kinetics as that of the transport of Fc 
receptor and influenza virus hemagglutinin proteins from 
the Golgi to the cell surface (Green et al., 1987). Thus, 
based on time constraints of transport, it was concluded 
that igp120 transport to lysosomes did not involve the 
plasma membrane. Similar conclusions were made for 
the mouse LAMP-1 protein based on the distribution of 
newly produced protein in cellular fractionation studies 
(D'Souza and August, 1986). Recent biotinylation and an- 
tibody binding studies with Igp120 have demonstrated 
that only a small portion of the produced protein became 
accessible to extracellular reagents, suggesting that cell- 
surface expression was not necessary prior to lysosomal 
transport (Harter and Mellman, 1992). 
In this report, we describe a lysosomally targeted pro- 
tein Which is undetectable by standard steady-state 
assays on the cell surface. Nevertheless, studies pre- 
sented here demonstrate that a significant proportion of 
the protein is expressed transiently on the cell surface 
prior to its lysosomal degradation. Thus, a transient cell- 
surface intermediate exists for this protein without any 
detectable accumulation at the plasma membrane. This 
raises the possibility that a similar pathway may be oper- 
ational for other lysosomal proteins for which surface 
localization has not been possible. 
We previously demonstrated that the #26 mutant RSV 
envelope glycoprotein was synthesized and processed 
normally. However, no substantial accumulation of glyco- 
protein could be detected on the cell surface by surface 
immunofluorescence or iodination studies. On the other 
hand, terminally glycosylated #26 proteins accumulated 
in the cell in the presence of chloroquine (Davis and 
Hunter, 1987). In order to reexamine the pathway for 
lysosomal targeting of this protein, we have incorporated 
a trypsin-sensitive cleavage mutation into the #26 protein 
and were able to demonstrate that the doubly mutant 
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FrG. 5. Localization of the internalized #26 glycoproteins in infected cells in the presence of chtoroquine. Cells expressing the #26 glycoprotein 
(A and B, identical plates) orno viral glycoproteins (C and D, identical plates) were incubated wit~ type-specific antibody for4 hr in the presence 
of chloroquine and fixed, as described in the legend to Fig. 4. Immunofluorescent staining with an FITC-conjugated anti-chicken antibody identified 
the distribution of the #26 proteins (A) with no detectable accumulation of the type-specific antibody in uninfected cells (C). For detection of 
lysosomal vesicles, the fixed cells were subsequently incubated in the presence of monoclonal antibody 1BS, followed by incubation with a Texas 
red conjugated anti-mouse antibody (B and D). Immunofluorescence of the doubly stained cells indicated that the vesicles containing the #26 
proteins are distinct from those b aring lysosomal markers. 
#26/$19 protein was accessible to trypsin in the culture 
medium. It appears that a major fraction of the mutant 
protein was being exposed on the cell surface. This con- 
clusion is based on the ratios of precursor to cleaved 
product, which accumulated in the presence of trypsin 
and chloroquine, in the wild-type and doubly mutant pro- 
teins. The possibility that the incorporation of the second 
mutation resulted in increased surface expression of the 
mutant protein was ruled out by the inability to detect 
surface glycoprotein by immunofluorescence on unfixed 
cells. 
Since it was possible that nonspecific uptake of trypsin 
and colocalization of enzyme and substrate in endosomal 
vesicles might allow cleavage of the mutant protein, we 
sought additional evidence for surface targeting. For 
these experiments, we determined whether the #26 pro- 
tein could induce specific endocytosis of reactive anti- 
bodies added to the culture medium of expressing cells. 
In the presence of chloroquine, antibodies reactive 
with the glycoprotein of the RSV Prague C strain (the 
parental virus strain from which the wild-type glycopro- 
tein was derived) accumulated within specific prelyso- 
somal vesicles in cells expressing the #26 mutant pro- 
teins. Antibodies reactive with another strain of RSV or 
antibodies reactive with another virus did not accumulate 
in intracytoplasmic vesicles. Therefore, this accumula- 
tion was specifically associated with the expression of 
the #26 protein, it seems unlikely that in this case the 
antibodies were being endocytosed nonspecifically into 
vesicles which then fused with mutant glycoprotein-con- 
taining vesicles since in the antibody-containing vesi- 
cles, the immunoglobulin appeared to be tightly associ- 
ated with the vesicle wall and those vesicles that stained 
for the endocytosed antibody also stained for Env protein. 
To rule out the possibility that the endocytosis and accu- 
mulation of the antibody was intrinsic to the anti-PrC 
antibody itself or was related to the SV40 expression 
system, we showed that expression of the M-PMV glyco- 
protein from the same expression system did not result 
in antibody accumulation. Thus, we have demonstrated 
by cleavage/activation and antibody uptake experiments 
that the #26 glycoprotein is targeted first to the cell sur- 
face prior to its rapid and complete endocytosis and 
transport to the lysosome. 
The mechanism by which the inserted charged residue 
directs these mutant glycoproteins to lysosomes remains 
unclear, it is evident that the inserted arginine does not 
disrupt membrane association, since no glycoprotein 
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was secreted into the culture medium (Davis and Hunter, 
1987). Moreover, the protein orientation in the cell mem- 
branes is also not affected, based on the antibody bind- 
ing studies and trypsin sensitivity data presented here. 
It is possible that the presence of the charged residue 
results in a perturbation in the membrane due to an 
attempt to exclude the positive charge of the arginine 
from the lipid environment. Interestingly, while deletions 
within the membrane-spanning domain of RSV (Hunter, 
1988) have demonstrated that a region of 16 amino acids 
was sufficient to anchor the protein in the membrane, 
such molecules were also more rapidly degraded in lyso- 
somes. 
A recently proposed model for the transmembrane re- 
gion of the RSV TM protein (Miller et aL, submitted for 
publication) would accommodate the presence of the 
arginine by allowing its charge to associate with the 
polar head groups in the lipid bilayer. It has been demon- 
strated that two cysteines surrounding the position of the 
inserted arginine are palmitylated (Miller etaL, submitted 
for publication). Substitution mutations which block pal- 
mitylation at the cysteine located 2 amino acids C-termi- 
nal to the arginine yield an RSV glycoprotein that is also 
more rapidly degraded. It is, therefore, possible that the 
#26 mutation affects palmitate addition at this critical 
residue. Alternatively, the insertion of the arginine resi- 
due may make the mutant protein interact more readily 
with the endocytosis machinery. 
Viral envelope proteins have been utilized extensively 
in the past few years to study endocytosis. Vesicular 
stomatitis virus (VSV) G protein is internalized in coated 
pits (Gottlieb etaL, 1986), and chimeric influenza hemag- 
glutininNSV G proteins have shown that the endocytosis 
signal in the VSV G protein resides in the cytoplasmic 
domain of the VSV G protein (Roth etaL, 1986). Chimeras 
between the VSV G protein and LEP100 have also been 
created for examining critical domains of LEP100 respon- 
sible for lysosomal targeting (Mathews et aL, 1992). The 
HN glycoprotein of the paramyxovirus SV5 was shown 
to be rapidly endocytosed and degraded in CV-1 cells 
by antibody-uptake xperiments (Ng et aL, 1989). Inser- 
tion of a tyrosine in the cytoplasmic domain of influenza 
HA protein, which is normally not endocytosed, resulted 
in the endocytosis of this molecule, demonstrating the 
involvement of cytoplasmic tyrosines in endocytosis (La- 
zarovits and Roth, 1988). 
Internalization signals have been proposed for various 
cellular receptor proteins, including the low density lipo- 
protein receptor (Chen eta/., 1990), the mannose-6-phos- 
phate receptor (Canfield et aL, 1991), the transferrin re- 
ceptor (Collawn et al., 1990; Girones et aL, 1991), etc. 
These proteins are known to be expressed on the cell 
surface prior to endocytosis in clathrin-coated pits, and 
an adaptor protein, HA-II, has been demonstrated to in- 
teract with cytoplasmic tyrosines of some of the mole- 
cules in coated pits (Glickman et aL, 1989). The internal- 
ization signals of the receptor molecules usually consist 
of four to six amino acids, typically including tyrosine. 
interestingly, there is a tetrapeptide motif, Tyr -Arg-Lys-  
Met, present in the cytoplasmic domain of the RSV TM 
protein which has homology with the proposed internal- 
ization signal of the human transferrin receptor, Tyr-X-  
Arg-Phe (Collawn et aL, 1990). Thus, it is possible that 
the inserted charge within the membrane-spanning do- 
main of the #26 protein results in an altered conformation 
of the cytoplasmic domain of the glycoprotein and that 
enhanced exposure of this putative internalization signal 
could result in the rapid endocytosis of the protein. We 
are currently examining this hypothesis by mutagenizing 
the putative internalization signal in the RSV TM protein. 
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